Genmab A/S (NASDAQ: GMAB) Stock Competitors & Peer Comparison
See GMAB's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GMAB and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GMAB | $53.87 | -0.37% | 33.1B | 40.60 | $1.33 | N/A |
| VRTX | $547.03 | -0.16% | 138.7B | 28.75 | $19.03 | N/A |
| MRNA | $248.69 | -0.85% | 100.6B | -30.51 | -$8.15 | N/A |
| REGN | $959.41 | +4.73% | 99.2B | 21.03 | $45.63 | +0.39% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $977.58 | +0.62% | 60.8B | 35.25 | $27.73 | N/A |
| ONC | $419.98 | -0.95% | 44.9B | 73.94 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $180.70 | -6.40% | 39.1B | -20.49 | -$8.82 | N/A |
| RVMDW | $8.65 | -13.59% | 37B | -0.98 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
GMAB vs VRTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, VRTX has a market cap of 138.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while VRTX trades at $547.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas VRTX's P/E ratio is 28.75. In terms of profitability, GMAB's ROE is +0.12%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, GMAB is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
GMAB vs MRNA Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MRNA has a market cap of 100.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MRNA trades at $248.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MRNA's P/E ratio is -30.51. In terms of profitability, GMAB's ROE is +0.12%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, GMAB is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
GMAB vs REGN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, REGN has a market cap of 99.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while REGN trades at $959.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas REGN's P/E ratio is 21.03. In terms of profitability, GMAB's ROE is +0.12%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GMAB is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
GMAB vs VRNA Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GMAB's ROE is +0.12%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, GMAB is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
GMAB vs ARGX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ARGX has a market cap of 60.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ARGX trades at $977.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ARGX's P/E ratio is 35.25. In terms of profitability, GMAB's ROE is +0.12%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, GMAB is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
GMAB vs ONC Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ONC has a market cap of 44.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ONC trades at $419.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ONC's P/E ratio is 73.94. In terms of profitability, GMAB's ROE is +0.12%, compared to ONC's ROE of +0.18%. Regarding short-term risk, GMAB is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
GMAB vs SGEN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GMAB's ROE is +0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GMAB is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
GMAB vs RVMD Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RVMD has a market cap of 39.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RVMD trades at $180.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RVMD's P/E ratio is -20.49. In terms of profitability, GMAB's ROE is +0.12%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, GMAB is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
GMAB vs RVMDW Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RVMDW has a market cap of 37B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RVMDW trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RVMDW's P/E ratio is -0.98. In terms of profitability, GMAB's ROE is +0.12%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, GMAB is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check RVMDW's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
GMAB vs ROIV Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ROIV has a market cap of 30.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ROIV trades at $41.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ROIV's P/E ratio is -39.81. In terms of profitability, GMAB's ROE is +0.12%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, GMAB is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
GMAB vs INSM Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, INSM has a market cap of 26.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while INSM trades at $120.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas INSM's P/E ratio is -42.82. In terms of profitability, GMAB's ROE is +0.12%, compared to INSM's ROE of -0.83%. Regarding short-term risk, GMAB is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
GMAB vs UTHR Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, UTHR has a market cap of 25.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while UTHR trades at $595.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas UTHR's P/E ratio is 21.30. In terms of profitability, GMAB's ROE is +0.12%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GMAB is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
GMAB vs INCY Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, INCY has a market cap of 24.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while INCY trades at $122.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas INCY's P/E ratio is 16.43. In terms of profitability, GMAB's ROE is +0.12%, compared to INCY's ROE of +0.07%. Regarding short-term risk, GMAB is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
GMAB vs BNTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while BNTX trades at $87.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas BNTX's P/E ratio is -11.37. In terms of profitability, GMAB's ROE is +0.12%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, GMAB is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
GMAB vs ALNY Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ALNY has a market cap of 21.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ALNY trades at $159.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ALNY's P/E ratio is 8.07. In terms of profitability, GMAB's ROE is +0.12%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, GMAB is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
GMAB vs BGNE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GMAB's ROE is +0.12%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, GMAB is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
GMAB vs DNA-WT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GMAB's ROE is +0.12%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, GMAB is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
GMAB vs EXEL Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, EXEL has a market cap of 17.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while EXEL trades at $70.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas EXEL's P/E ratio is 20.20. In terms of profitability, GMAB's ROE is +0.12%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, GMAB is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
GMAB vs NBIX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while NBIX trades at $174.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas NBIX's P/E ratio is 25.20. In terms of profitability, GMAB's ROE is +0.12%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, GMAB is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
GMAB vs ASND Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ASND has a market cap of 17.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ASND trades at $259.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ASND's P/E ratio is -107.14. In terms of profitability, GMAB's ROE is +0.12%, compared to ASND's ROE of +1.90%. Regarding short-term risk, GMAB is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
GMAB vs JAZZ Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while JAZZ trades at $248.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas JAZZ's P/E ratio is 9.26. In terms of profitability, GMAB's ROE is +0.12%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, GMAB is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
GMAB vs BBIO Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, BBIO has a market cap of 15.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while BBIO trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas BBIO's P/E ratio is -26.16. In terms of profitability, GMAB's ROE is +0.12%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, GMAB is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
GMAB vs SMMT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, SMMT has a market cap of 13.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while SMMT trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas SMMT's P/E ratio is -14.86. In terms of profitability, GMAB's ROE is +0.12%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, GMAB is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
GMAB vs KRTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GMAB's ROE is +0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GMAB is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
GMAB vs HALO Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, HALO has a market cap of 11.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while HALO trades at $101.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas HALO's P/E ratio is 18.97. In terms of profitability, GMAB's ROE is +0.12%, compared to HALO's ROE of +5.44%. Regarding short-term risk, GMAB is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check HALO's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
GMAB vs KYMR Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, KYMR has a market cap of 11.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while KYMR trades at $134.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas KYMR's P/E ratio is -37.25. In terms of profitability, GMAB's ROE is +0.12%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, GMAB is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check KYMR's competition here
Bio-Techne Corporation (NASDAQ: TECH)
GMAB vs TECH Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TECH's P/E ratio is 37.53. In terms of profitability, GMAB's ROE is +0.12%, compared to TECH's ROE of +0.08%. Regarding short-term risk, GMAB is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
GMAB vs BMRN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while BMRN trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas BMRN's P/E ratio is 28.04. In terms of profitability, GMAB's ROE is +0.12%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, GMAB is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
GMAB vs RNAM Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GMAB's ROE is +0.12%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, GMAB is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RNAM's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
GMAB vs PCVX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, PCVX has a market cap of 10.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while PCVX trades at $68.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas PCVX's P/E ratio is -8.99. In terms of profitability, GMAB's ROE is +0.12%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, GMAB is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
GMAB vs SYRE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, SYRE has a market cap of 10.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while SYRE trades at $106.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas SYRE's P/E ratio is -54.78. In terms of profitability, GMAB's ROE is +0.12%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, GMAB is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
GMAB vs TGTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TGTX has a market cap of 10.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TGTX trades at $65.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TGTX's P/E ratio is 23.83. In terms of profitability, GMAB's ROE is +0.12%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, GMAB is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TGTX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
GMAB vs MDGL Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MDGL trades at $433.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MDGL's P/E ratio is -33.83. In terms of profitability, GMAB's ROE is +0.12%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, GMAB is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MDGL's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
GMAB vs PRAX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, PRAX has a market cap of 9.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while PRAX trades at $346.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas PRAX's P/E ratio is -26.78. In terms of profitability, GMAB's ROE is +0.12%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, GMAB is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PRAX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
GMAB vs RXDX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GMAB's ROE is +0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GMAB is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RXDX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
GMAB vs KRYS Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, KRYS has a market cap of 9.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while KRYS trades at $308.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas KRYS's P/E ratio is 38.70. In terms of profitability, GMAB's ROE is +0.12%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, GMAB is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check KRYS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
GMAB vs NUVL Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas NUVL's P/E ratio is -21.79. In terms of profitability, GMAB's ROE is +0.12%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, GMAB is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
GMAB vs CRNX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CRNX's P/E ratio is -16.86. In terms of profitability, GMAB's ROE is +0.12%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, GMAB is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
GMAB vs PTGX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while PTGX trades at $134.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas PTGX's P/E ratio is 130.93. In terms of profitability, GMAB's ROE is +0.12%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, GMAB is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
GMAB vs IMGN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GMAB's ROE is +0.12%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GMAB is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check IMGN's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
GMAB vs APGE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas APGE's P/E ratio is -31.19. In terms of profitability, GMAB's ROE is +0.12%, compared to APGE's ROE of -0.30%. Regarding short-term risk, GMAB is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
GMAB vs BPMC Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GMAB's ROE is +0.12%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, GMAB is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
GMAB vs CERE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CERE's P/E ratio is -16.47. In terms of profitability, GMAB's ROE is +0.12%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GMAB is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
GMAB vs CYTK Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CYTK trades at $58.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CYTK's P/E ratio is -8.11. In terms of profitability, GMAB's ROE is +0.12%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, GMAB is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CYTK's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
GMAB vs TWST Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TWST has a market cap of 8.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TWST trades at $122.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TWST's P/E ratio is -55.22. In terms of profitability, GMAB's ROE is +0.12%, compared to TWST's ROE of -0.30%. Regarding short-term risk, GMAB is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TWST's competition here
Abivax S.A. (NASDAQ: ABVX)
GMAB vs ABVX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ABVX trades at $91.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ABVX's P/E ratio is -14.98. In terms of profitability, GMAB's ROE is +0.12%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, GMAB is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
GMAB vs AXSM Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, AXSM has a market cap of 7.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while AXSM trades at $149.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas AXSM's P/E ratio is -38.97. In terms of profitability, GMAB's ROE is +0.12%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, GMAB is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check AXSM's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
GMAB vs RYTM Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RYTM trades at $112.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RYTM's P/E ratio is -36.05. In terms of profitability, GMAB's ROE is +0.12%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, GMAB is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RYTM's competition here
Immunovant, Inc. (NASDAQ: IMVT)
GMAB vs IMVT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while IMVT trades at $37.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas IMVT's P/E ratio is -13.13. In terms of profitability, GMAB's ROE is +0.12%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, GMAB is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
GMAB vs TXG Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TXG has a market cap of 7.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TXG trades at $62.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TXG's P/E ratio is -105.17. In terms of profitability, GMAB's ROE is +0.12%, compared to TXG's ROE of -0.08%. Regarding short-term risk, GMAB is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TXG's competition here
Metsera, Inc. (NASDAQ: MTSR)
GMAB vs MTSR Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GMAB's ROE is +0.12%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, GMAB is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
GMAB vs IBRX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, IBRX has a market cap of 7.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while IBRX trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas IBRX's P/E ratio is -6.88. In terms of profitability, GMAB's ROE is +0.12%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, GMAB is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check IBRX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
GMAB vs ORKA Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ORKA trades at $107.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ORKA's P/E ratio is -55.24. In terms of profitability, GMAB's ROE is +0.12%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, GMAB is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ORKA's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
GMAB vs ARWR Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ARWR has a market cap of 7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ARWR trades at $49.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ARWR's P/E ratio is -21.94. In terms of profitability, GMAB's ROE is +0.12%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, GMAB is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ARWR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
GMAB vs CAI Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CAI trades at $24.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CAI's P/E ratio is 68.64. In terms of profitability, GMAB's ROE is +0.12%, compared to CAI's ROE of +0.16%. Regarding short-term risk, GMAB is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CAI's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
GMAB vs KOD Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, KOD has a market cap of 6.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while KOD trades at $109.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas KOD's P/E ratio is -26.22. In terms of profitability, GMAB's ROE is +0.12%, compared to KOD's ROE of -2.73%. Regarding short-term risk, GMAB is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
GMAB vs MRUS Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GMAB's ROE is +0.12%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, GMAB is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
GMAB vs ACLX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ACLX's P/E ratio is -28.27. In terms of profitability, GMAB's ROE is +0.12%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, GMAB is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
GMAB vs RETA Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RETA's P/E ratio is -66.29. In terms of profitability, GMAB's ROE is +0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GMAB is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RETA's competition here
Veradermics, Incorporated (NYSE: MANE)
GMAB vs MANE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MANE has a market cap of 6.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MANE trades at $156.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MANE's P/E ratio is -49.73. In terms of profitability, GMAB's ROE is +0.12%, compared to MANE's ROE of -0.20%. Regarding short-term risk, GMAB is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check MANE's competition here
CG Oncology Inc. (NASDAQ: CGON)
GMAB vs CGON Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CGON trades at $72.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CGON's P/E ratio is -26.99. In terms of profitability, GMAB's ROE is +0.12%, compared to CGON's ROE of -0.25%. Regarding short-term risk, GMAB is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CGON's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
GMAB vs LGND Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while LGND trades at $316.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas LGND's P/E ratio is 34.78. In terms of profitability, GMAB's ROE is +0.12%, compared to LGND's ROE of +0.05%. Regarding short-term risk, GMAB is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check LGND's competition here
Belite Bio, Inc (NASDAQ: BLTE)
GMAB vs BLTE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while BLTE trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas BLTE's P/E ratio is -83.39. In terms of profitability, GMAB's ROE is +0.12%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, GMAB is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
GMAB vs CNTA Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CNTA's P/E ratio is -22.63. In terms of profitability, GMAB's ROE is +0.12%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, GMAB is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
GMAB vs MIRM Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MIRM trades at $94.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MIRM's P/E ratio is -6.50. In terms of profitability, GMAB's ROE is +0.12%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, GMAB is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
GMAB vs TERN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TERN's P/E ratio is -51.41. In terms of profitability, GMAB's ROE is +0.12%, compared to TERN's ROE of -0.14%. Regarding short-term risk, GMAB is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check TERN's competition here
Erasca, Inc. (NASDAQ: ERAS)
GMAB vs ERAS Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ERAS trades at $16.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ERAS's P/E ratio is -18.06. In terms of profitability, GMAB's ROE is +0.12%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, GMAB is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
GMAB vs SRRK Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while SRRK trades at $46.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas SRRK's P/E ratio is -13.51. In terms of profitability, GMAB's ROE is +0.12%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, GMAB is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
GMAB vs CDTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GMAB's ROE is +0.12%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, GMAB is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
GMAB vs ABCM Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GMAB's ROE is +0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GMAB is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
GMAB vs ISEE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GMAB's ROE is +0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GMAB is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
GMAB vs PTCT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while PTCT trades at $64.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas PTCT's P/E ratio is -46.36. In terms of profitability, GMAB's ROE is +0.12%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, GMAB is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
GMAB vs APLS Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas APLS's P/E ratio is 38.35. In terms of profitability, GMAB's ROE is +0.12%, compared to APLS's ROE of +0.40%. Regarding short-term risk, GMAB is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check APLS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
GMAB vs EWTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, EWTX has a market cap of 5.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while EWTX trades at $47.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas EWTX's P/E ratio is -25.71. In terms of profitability, GMAB's ROE is +0.12%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, GMAB is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check EWTX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
GMAB vs COGT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while COGT trades at $29.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas COGT's P/E ratio is -13.93. In terms of profitability, GMAB's ROE is +0.12%, compared to COGT's ROE of -0.71%. Regarding short-term risk, GMAB is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check COGT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
GMAB vs DNTH Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while DNTH trades at $89.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas DNTH's P/E ratio is -21.52. In terms of profitability, GMAB's ROE is +0.12%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, GMAB is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
GMAB vs TVTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TVTX trades at $52.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TVTX's P/E ratio is -115.64. In terms of profitability, GMAB's ROE is +0.12%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, GMAB is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check TVTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
GMAB vs ADPT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ADPT has a market cap of 4.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ADPT trades at $29.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ADPT's P/E ratio is -73.02. In terms of profitability, GMAB's ROE is +0.12%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, GMAB is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ADPT's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
GMAB vs IONS Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, IONS has a market cap of 4.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while IONS trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas IONS's P/E ratio is -8.66. In terms of profitability, GMAB's ROE is +0.12%, compared to IONS's ROE of -1.20%. Regarding short-term risk, GMAB is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check IONS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
GMAB vs DFTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while DFTX trades at $34.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas DFTX's P/E ratio is N/A. In terms of profitability, GMAB's ROE is +0.12%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, GMAB is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
GMAB vs FOLD Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas FOLD's P/E ratio is -161.00. In terms of profitability, GMAB's ROE is +0.12%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, GMAB is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
GMAB vs AKRO Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GMAB's ROE is +0.12%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, GMAB is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
GMAB vs ALPN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GMAB's ROE is +0.12%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GMAB is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ALPN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
GMAB vs CRSP Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CRSP has a market cap of 4.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CRSP trades at $45.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CRSP's P/E ratio is -9.61. In terms of profitability, GMAB's ROE is +0.12%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, GMAB is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
GMAB vs RLAY Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RLAY trades at $19.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RLAY's P/E ratio is -12.56. In terms of profitability, GMAB's ROE is +0.12%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, GMAB is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RLAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
GMAB vs TNGX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TNGX trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TNGX's P/E ratio is -31.00. In terms of profitability, GMAB's ROE is +0.12%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, GMAB is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
GMAB vs OPT Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas OPT's P/E ratio is -1.52. In terms of profitability, GMAB's ROE is +0.12%, compared to OPT's ROE of +1.18%. Regarding short-term risk, GMAB is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
GMAB vs PRTC Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas PRTC's P/E ratio is -3.78. In terms of profitability, GMAB's ROE is +0.12%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, GMAB is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check PRTC's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
GMAB vs XENE Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while XENE trades at $42.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas XENE's P/E ratio is -8.96. In terms of profitability, GMAB's ROE is +0.12%, compared to XENE's ROE of -0.40%. Regarding short-term risk, GMAB is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check XENE's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
GMAB vs MRTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GMAB's ROE is +0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GMAB is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check MRTX's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
GMAB vs AMLX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, AMLX has a market cap of 4.1B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while AMLX trades at $31.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas AMLX's P/E ratio is -21.20. In terms of profitability, GMAB's ROE is +0.12%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, GMAB is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check AMLX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
GMAB vs ABCL Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ABCL trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ABCL's P/E ratio is -22.13. In terms of profitability, GMAB's ROE is +0.12%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, GMAB is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
GMAB vs CPRX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CPRX's P/E ratio is 17.49. In terms of profitability, GMAB's ROE is +0.12%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GMAB is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CPRX's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
GMAB vs TARS Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, TARS has a market cap of 3.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while TARS trades at $76.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas TARS's P/E ratio is -70.42. In terms of profitability, GMAB's ROE is +0.12%, compared to TARS's ROE of -2.46%. Regarding short-term risk, GMAB is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for GMAB.Check TARS's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
GMAB vs ELVN Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while ELVN trades at $51.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas ELVN's P/E ratio is -30.65. In terms of profitability, GMAB's ROE is +0.12%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, GMAB is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
GMAB vs RYZB Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GMAB's ROE is +0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GMAB is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check RYZB's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
GMAB vs IOVA Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, IOVA has a market cap of 3.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while IOVA trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas IOVA's P/E ratio is -11.08. In terms of profitability, GMAB's ROE is +0.12%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, GMAB is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check IOVA's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
GMAB vs CBAY Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GMAB's ROE is +0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GMAB is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
GMAB vs VKTX Comparison November 2026
Genmab A/S (NASDAQ: GMAB) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GMAB stands at 33.1B. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, GMAB is priced at $53.87 on the NASDAQ, while VKTX trades at $28.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GMAB currently has a P/E ratio of 40.60, whereas VKTX's P/E ratio is -5.27. In terms of profitability, GMAB's ROE is +0.12%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, GMAB is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for GMAB.Check VKTX's competition here